enGene FY2025 net loss $117.3M; LEGEND pivotal cohort complete (125 pts), 62% CR at 6 months; cash runway to 2H 2028

enGene Therapeutics Inc.

2025-FY EPS reported $2.29

FY2025 net loss $117.3M ($2.29/sh) vs $55.1M ($1.46/sh) in 2024; R&D expenses up $56.2M to $123.2M total OpEx.
LEGEND pivotal cohort enrollment complete with 125 patients; preliminary CR rate 62% at 6 months (post-amendment patients).
Cash, equivalents, and marketable securities $202.3M at Oct 31, 2025; plus $140.1M net from Nov offering; runway into 2H 2028.
FDA selected enGene for CDRP program to support CMC readiness; BLA filing for detalimogene planned for 2H 2026.
Appointed Dr. Hussein Sweiti as CMO in September; he previously led J&J's bladder cancer portfolio leading to FDA approval.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.